01
The "fourth highest" population is nearly 180 million,
The gout market demand is strong
As one of the common chronic pains, the incidence of gout has been increasing in recent years. According to the 2021 White Paper on Trends in Hyperuricemia and Gout in China, as of 2020, the number of people with hyperuricemia and gout in the world is 930 million, the number of hyperuricemia in China is about 177 million, and the number of gout patients is about 14.66 million: the average age of gout patients is 48 years old, and the incidence of middle-aged and elderly patients is high, but in recent years, it has shown a younger trend.
In addition, Frost & Sullivan predicts that the number of people suffering from hyperuricemia and gout in mainland China will reach 240 million by 2030, which is the "fourth highest" health need that is often overlooked. The domestic gout drug market will grow from 900 million yuan in 2016 to 2.8 billion yuan in 2020, and is expected to grow to 10.8 billion yuan in 2030.
According to the CMH data of Zhongkang, at present, the drugs for gout/hyperuricemia in the out-of-hospital retail terminal market are mainly febuxostat and benzbromarone. In 2023, the sales scale of the gout/hyperuricemia drug retail terminal market will be 1.155 billion yuan, a slight year-on-year decline, while the sales volume is basically the same as in the past two years.
Gout/hyperuricemia drugs - retail terminal market sales scale
Data source: Zhongkang Kaisi system
Among them, febuxostat, as a large gout product with an annual sales of more than 2 billion yuan in all channels in China, has declined in sales scale after being included in centralized procurement, and its sales at retail terminals will be 748 million yuan in 2023. It is worth noting that despite the decline in sales of febuxostat, its sales in the out-of-hospital channel continue to climb. As the leading brand of febuxostat, Uniton will occupy nearly 60% of the market share of the febuxostat retail market in 2023, with a year-on-year increase of 12.6% in sales.
Febuxostat - retail terminal market sales
Data source: Zhongkang Kaisi system
Febuxostat-Retail End Market Volume Trends
Data source: Zhongkang Kaisi system
02
empowering chain chronic disease management,
Promote business with service
Gout/hyperuricemia has increasingly become one of the common chronic diseases after the "three highs", but the public attaches far less importance to it than the "three highs".
In order to improve the health awareness of hyperuricemia and gout, and develop good living and eating habits, as early as 2016, Wanbang Pharma launched the "420 National Gout Day Activity" with experts and scholars at home and abroad to help the public remember the diagnostic criteria of hyperuricemia of 420umol/L on April 20, so as to achieve early prevention, early treatment and early benefit.
On April 20 this year, the ninth "National Gout Day", Wanbang Pharma invited experts from rheumatology and immunology and doctors from all over the world to be guests in the live broadcast room of "Famous Doctors Talk", through vivid cases and medical knowledge explanations, and in the way of combining traditional Chinese and Western medicine, to help the public grasp the key points of gout prevention and treatment.
On the other hand, retail pharmacies, as the "capillaries" of the primary medical service circle, play an important role in the management of chronic diseases such as gout. This year, Wanbang Pharma continued to work with major chains to provide a wealth of health activities for community residents.
In terms of health science popularization, Wanbang Pharma joined hands with chain pharmacies to strengthen gout health education for the public online and offline through activities such as in-store health science popularization, a gout talent competition covering 13,000 people for five days, more than 30 health free clinics and live broadcasts, etc., and also enhanced the awareness of pharmacy staff on the value of Uliton products, so as to facilitate more scientific medication guidance for patients in the future, so that more patients can benefit.
At the same time, through more than 1,000 in-store uric acid testing activities, more than 1,000 health return visits and preferential activities, community residents can more intuitively understand their uric acid levels, realize the closed-loop of the whole process of screening, diagnosis, medication, tracking and monitoring, help gout patients improve compliance, and professional health services also bring higher customer flow and sales to pharmacies.
In addition, Wanbang Pharmaceutical and the chain launched the Brand Best Friends Competition, attracting more than 384 store employees to participate, receiving more than 20,000 visits and more than 10,000 votes, empowering the chain with high-quality brands, strengthening the public's awareness of Youlitong and cooperative chains and participating store staff, helping them to get closer to community residents, building trust, helping store staff to grasp the health of patients more comprehensively and give personalized health guidance.
03
Ten years of deep cultivation,
Help the whole people to prevent and treat gout
In June 2013, Wanbang Pharmaceutical Youlitong was officially launched as the first febuxostat tablet in China, and quickly opened the market and became a leading brand in the field of anti-gout. In 2020, Wanbang Pharma, as the winning bidder of febuxostat tablets 40mg, continued to ensure the supply of high-quality products and benefited more patients. According to the CMH data of Zhongkang, Wanbang Pharma Youlitong has achieved the first market share in the field of anti-gout in the retail market for 7 consecutive years, and is the core product of Fosun Pharma's metabolism and digestive system.
Over the past ten years, Wanbang Pharma has been committed to providing professional and cost-effective products and health services for patients inside and outside the hospital, helping to improve the level of gout prevention and treatment in the country, which is also the original intention of Wanbang Pharma to launch the "420 National Gout Day" activity.
Over the years, Wanbang Pharmaceutical has combined with the pharmacy terminal to achieve a exponential increase in product sales and coverage of patients by creating the IP of "420 National Gout Day". In addition, Wanbang Pharma has joined hands with many chains to launch the "China High Uric Acid Public Welfare Screening Tour" to track patients in chain pharmacies from four aspects: consultation rate, awareness rate, treatment rate and effective maintenance rate, which not only makes the products well promoted in the out-of-hospital retail channels, but also helps the chain gradually establish a chronic disease management system, which has become a model of successful marketing cases of the "drug + test" model in the field of chronic diseases in the industry.
In the future, Wanbang Pharma will continue to work with chain partners to provide the public with medical knowledge popularization activities and smart solutions for healthy life through public welfare activities such as "420 National Gout Day", so as to help improve the level of gout prevention and treatment at the grassroots level. At the same time, Wanbang Pharma will continue to empower chain pharmacies, work together to build a good pharmaceutical retail ecology, build a more professional and valuable platform, and better serve consumers.
END